Lawrence A. Leiter

MDCM, FRCPC, FACP, FACE, FAHA

Investigator

Biography

Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.

 

Recent Publications

  1. O'Donoghue, ML, Kato, ET, Mosenzon, O, Murphy, SA, Cahn, A, Herrera, M et al.. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 2021; :. doi: 10.1007/s00125-021-05399-2. PubMed PMID:33611623 .
  2. Riddle, MC, Bakris, G, Blonde, L, Boulton, AJM, D'Alessio, D, DiMeglio, LA et al.. A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care. 2021;44 (1):8-10. doi: 10.2337/dci20-0071. PubMed PMID:33571952 .
  3. Riddle, MC, Gerstein, HC, Xavier, D, Cushman, WC, Leiter, LA, Raubenheimer, PJ et al.. Efficacy and Safety of Dulaglutide in Older Patients: A Post-hoc Analysis of the REWIND trial. J Clin Endocrinol Metab. 2021; :. doi: 10.1210/clinem/dgab065. PubMed PMID:33537745 .
  4. Zurbau, A, Smircic Duvnjak, L, Magas, S, Jovanovski, E, Miocic, J, Jenkins, AL et al.. Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial. Eur J Nutr. 2021; :. doi: 10.1007/s00394-020-02434-7. PubMed PMID:33486572 .
  5. Mason, T, Coelho-Filho, OR, Verma, S, Chowdhury, B, Zuo, F, Quan, A et al.. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC Cardiovasc Imaging. 2021; :. doi: 10.1016/j.jcmg.2020.10.017. PubMed PMID:33454272 .
  6. McEwan, P, Morgan, AR, Boyce, R, Bergenheim, K, Gause-Nilsson, IAM, Bhatt, DL et al.. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.14308. PubMed PMID:33368855 .
  7. Zelniker, TA, Morrow, DA, Mosenzon, O, Goodrich, EL, Jarolim, P, Murphy, SA et al.. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2020; :. doi: 10.1002/ejhf.2073. PubMed PMID:33269486 .
  8. Langer, A, Tan, M, Goodman, SG, Grégoire, J, Lin, PJ, Mancini, GBJ et al.. Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. Int J Clin Pract. 2020; :e13861. doi: 10.1111/ijcp.13861. PubMed PMID:33244861 .
  9. Dagenais, GR, Rydén, L, Leiter, LA, Lakshmanan, M, Dyal, L, Probstfield, JL et al.. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol. 2020;19 (1):199. doi: 10.1186/s12933-020-01179-1. PubMed PMID:33239067 PubMed Central PMC7690176.
  10. Bhatt, DL, Szarek, M, Steg, PG, Cannon, CP, Leiter, LA, McGuire, DK et al.. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384 (2):117-128. doi: 10.1056/NEJMoa2030183. PubMed PMID:33200892 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto
X